REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
04/27/2026
Back to search
Official data from USPTO
OBLIQUE THERAPEUTICS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
OBLIQUE THERAPEUTICS
ST13
US500000088178276Class
42
Filing
88178276
Registration
6335551
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
38
Latest update
04/28/2026
Trademark type
Word
Nice classes
42
Filing date
11/01/2018
Registration date
04/27/2021
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
04/27/2021
Last transaction
04/28/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
12/31/2015
First use in commerce
12/31/2015
Drawing code
4
Owner type
99
Owner location
Göteborg, SE
Examiner
PAQUIN, SAMUEL ROBERT
Law office
L10
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
Oblique Therapeutics AB
Oblique Therapeutics AB
Representatives
James F. Keenan, Jr. BERNSTEIN, SHUR, SAWYER & NELSON
Technical classification
Nice Classes
Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 42
Research and development regarding pharmaceuticals and pharmaceutical preparations; Research and development for the pharmaceutical industry; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Conducting early evaluations in the field of new pharmaceuticals; Medical research in the field of cancer; Pharmaceutical research; Biological research; Bacteriological research; Scientific research for medical purposes in the area of cancerous diseases; Cell separation technology research services; Medical research laboratory services; Laboratory research services relating to the production of monoclonal antibodies; Laboratory research services relating to pharmaceuticals; Pharmaceutical products development; Scientific research and development; Science and technology research services in the field of medicine; Technological analysis services in the field of medical research
Publications
History of USPTO decisions and trademark events.
38 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
04/27/2021
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
03/23/2021
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
03/20/2021
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
03/17/2021
SUPC
STATEMENT OF USE PROCESSING COMPLETE
03/16/2021
EX3G
SOU EXTENSION 3 GRANTED
03/16/2021
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
03/16/2021
IUAF
USE AMENDMENT FILED
03/02/2021
EXT3
SOU EXTENSION 3 FILED
03/02/2021
EEXT
SOU TEAS EXTENSION RECEIVED
03/02/2021
EISU
TEAS STATEMENT OF USE RECEIVED
03/02/2021
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
08/14/2020
EX2G
SOU EXTENSION 2 GRANTED
08/12/2020
EXT2
SOU EXTENSION 2 FILED
08/12/2020
EEXT
SOU TEAS EXTENSION RECEIVED
08/12/2020
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
02/29/2020
EX1G
SOU EXTENSION 1 GRANTED
02/20/2020
EXT1
SOU EXTENSION 1 FILED
02/20/2020
EEXT
SOU TEAS EXTENSION RECEIVED
02/20/2020
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
02/20/2020
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
02/20/2020
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
02/20/2020
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
09/03/2019
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
07/09/2019
PUBO
PUBLISHED FOR OPPOSITION
07/09/2019
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
06/19/2019
ALIE
ASSIGNED TO LIE
06/03/2019
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
05/21/2019
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
05/20/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
05/20/2019
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
05/20/2019
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
02/07/2019
GNRT
NON-FINAL ACTION E-MAILED
02/07/2019
CNRT
NON-FINAL ACTION WRITTEN
02/07/2019
DOCK
ASSIGNED TO EXAMINER
02/07/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
11/16/2018
NWAP
NEW APPLICATION ENTERED
11/05/2018
Continuous trademark protection
Get notified about every new filing that threatens OBLIQUE THERAPEUTICS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.